PHILADELPHIA, Aug. 23, 2016 (GLOBE NEWSWIRE)
"“In Argentina, rintatolimod (Ampligen) has just been commercially approved for the severe disabling form of ME/CFS. The number of patients with ME/CFS is estimated to be over three million worldwide, however, only a portion of these have the severe and disabling form of the disease which we are targeting with this drug,” stated Tom Equels."
"Several post-approval activities are required to be completed before product launch, including manufacturing site inspections and reimbursement evaluation by the Health Services Authority (SSS), the central health authority in Argentina."
Great blog, thanks. I just want to share a couple of great articles for doctors, family, friends and other skeptics.
ReplyDeleteThe Faces Of ME: Missing 7 Years Of My Life –
http://huff.to/2bvIoJP
Learning Firsthand About Chronic Fatigue Syndrome – http://nyti.ms/1as74hv
#StopTheStigma #ME #CFS #MillionsMissing #CureME